Drug intelligence / Profile preview

CUG105

Development stage: Preclinical
Lead developer: Cugene
Modality: Vaccines & Immunotherapeutics, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration: Parenteral[1]

Overview

CUG105 is a next-generation long-acting interleukin-15 (IL-15) therapeutic developed by Cugene. It is designed to harness specific immune cells for the treatment of solid tumors and bladder cancer. As an IL-15 replacement and T lymphocyte stimulant, it acts as an immunotherapy and antineoplastic agent by stimulating the proliferation and activation of T cells, which play a critical role in anti-tumor immunity. The drug is classified as a new molecular entity and has not been granted orphan drug status. As of April 2022, it was in preclinical development for both bladder cancer and solid tumors[1].

Targets

IL15RA (Interleukin-15 receptor subunit alpha)IL2RB (IL-2 receptor beta chain)CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on CUG105.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CUG105.